加科思-B(01167.HK)將於美國癌症研究協會公布三項臨床前研究資料
加科思-B(01167.HK)公布,將於4月14至19日舉行的2023年美國癌症研究協會(AACR)年會上,以摘要形式公布三項臨床前研究資料,包括KRASmulti抑制劑JAB-23425、CD73-STING iADC JAB-X1800和極光激(酉每)A抑制劑JAB-2485。
公司指出,KRASmulti抑制劑JAB-23425作為廣譜KRAS抑制劑,可同時抑制KRAS的活性及非活性狀態,並對HRAS、NRAS具有良好的選擇性。JAB-23425能顯著抑制包括G12D、G12V、G13D在內的多種KRAS突變腫瘤,以及KRAS野生型擴增腫瘤。JAB-23425對非KRAS依賴的細胞無影響。KRASmulti抑制劑有望解決KRAS突變腫瘤患者的臨床未滿足需求。JAB-23425是加科思KRASmulti系列分子的先導化合物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.